Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
4.18 Mб
Скачать

13

Testing hypotheses about the ratio of two population parameters

Learning objectives

When you have finished this chapter you should be able to:

Describe the usual form of the null hypothesis in the context of testing the ratio of two population parameters

Outline the differences between tests of ratios and tests of differences. Interpret published results on tests of risk and odds ratios.

Testing the risk ratio

In Chapter 11 you saw that if the confidence interval for a sample risk ratio contains 1, then the population risk ratio is most probably not statistically significant, i.e. not significantly different from 1. This in turn means that the risk factor in question is not a statistically significant risk. You can also use the hypothesis test approach to find out whether any departure in the sample risk ratio from 1 is statistically significant, or is more likely due to chance. The null hypothesis

Medical Statistics from Scratch, Second Edition David Bowers

C 2008 John Wiley & Sons, Ltd

156 CH 13 TESTING HYPOTHESES ABOUT THE RATIO OF TWO POPULATION PARAMETERS

is that the population risk ratio equals 1, the alternate hypothesis is that it isn’t equal to 1. That is:

H0: population risk ratio = 1

H1: population risk ratio =1

In other words, if H0 is true, the risk factor in question does not significantly increase or decrease the risk for the condition or disease. If the associated p value is less than 0.05 (or 0.01), you can reject the null hypothesis H0, and conclude that the population risk ratio in question is statistically significant, and the risk factor in question is a statistically significant risk.

An example from practice

Table 13.1 is from a randomised trial into the efficacy of long-term treatment with subcutaneous heparin in unstable coronary-artery disease (FRISC II Investigators 1999), and shows the risk ratios, 95 per cent confidence intervals and p values for a number of clinical outcomes, in two independent groups, one group given heparin, the other a placebo.

As you can see from the p values in the last column, three out of the six risk ratios were statistically significant: death, myocardial infarction or both, at one month (p value = 0.048); death, myocardial infarction or revascularisation, at one month (p value = 0.001); and death, myocardial infarction or revascularisation, at three months (p value = 0.031). All three of these p values are less than 0.05, the remaining three are all greater than 0.05. Notice that these results are confirmed by the corresponding 95 per cent confidence intervals.

Table 13.1 Risk ratios, 95 per cent confidence intervals, and p-values, for a number of clinical outcomes, at 1 month, 3 months and 6 months, in two independent groups, one group given heparin and the other group a placebo. Reprinted courtesy of Elsevier (The Lancet, 1999, Vol No. 354, page 701–7)

 

Dalteparin

Placebo

Risk ratio

 

Variable

(n = 1129)

(n = 1121)

(95% CI)

p

1 month

 

 

 

 

 

 

Death, MI, or both

70

(6.2%)

95

(8.4%)

0.73 (0.54–0.99)

0.048

Death, MI, or revascularisation

220

(19.5%)

288

(25.7%)

0.76 (0.65–0.89)

0.001

3 months

 

 

 

 

 

 

Death, MI, or both

113

(10.0%)

126

(11.2%)

0.89 (0.70–1.13)

0.34

Death, MI, or revascularisation

328

(29.1%)

374

(33.4%)

0.87 (0.77–0.99)

0.031

6 months

 

 

 

 

 

 

Death, MI, or both

148

(13.3%)

145

(13.1%)

1.01 (0.82–1.25)

0.93

Death, MI, or revascularisation

428

(38.4%)

440

(39.9%)

0.96 (0.87–1.07)

0.50

 

 

 

 

 

 

 

MI = myocardial infarction.

Dalteparin (n = 1115), placebo (n = 1103).

TESTING THE RISK RATIO

157

Table 13.2 Relative risk for a number of non-cerebral bleeding complications in patients receiving tenecteplase compared to those receiving alteplase, in the treatment of acute myocardial infarction. Reprinted courtesy of Elsevier (The Lancet, 1999, Vol No. 354, page 716–21)

 

Frequency (%)

 

 

 

 

 

 

 

 

 

 

Tenecteplase

Alteplase

Relative risk

 

Complication

(n = 8461)

(n = 8488)

 

(95% CI)

p

Reinfarction

4.1

3.8

 

1.078

(0.929–1.250)

0.325

Recurrent angina

19.4

19.5

 

0.995

(0.935–1.058)

0.877

Sustained hypotension

15.9

16.1

 

0.988

(0.921–1.058)

0.737

Cardiogenic shock

3.9

4.0

 

0.965

(0.832–1.119)

0.664

Major arrhythmias

20.5

21.2

 

0.968

(0.913–1.027)

0.281

Pericarditis

3.0

2.6

 

1.124

(0.941–1.343)

0.209

Invasive cardiac procedures

 

 

 

 

 

 

PTCA

24.0

23.9

 

1.006

(0.953–1.061)

0.843

Stent placement

19.0

19.7

 

0.968

(0.910–1.029)

0.302

CABG

5.5

6.2

 

0.884

(0.783–0.999)

0.049

IABP

2.6

2.7

 

0.968

(0.805–1.163)

0.736

Killip class >I

6.1

7.0

 

0.991

(0.982–0.999)

0.026

Tamponade or cardiac rupture

0.6

0.7

 

0.816

(0.558–1.193)

0.332

Acute mitral regurgitation

0.6

0.7

 

0.886

(0.613–1.281)

0.571

Ventricular septum defect

0.3

0.3

 

0.817

(0.466–1.434)

0.568

Anaphylaxis

0.1

0.2

 

0.376

(0.147–0.961)

0.052

Pulmonary embolism

0.09

0.04

 

2.675

(0.710–10.080)

0.145

 

 

 

 

 

 

 

PTCA = Percutaneous transluminal coronary angioplasty; CABG = coronary-artery bypass graft; IABP = Intra-aortic balloon pump.

Exercise 13.1 Table 13.2 is from a double blind RCT to assess the efficacy of tenecteplase as a possible alternative to alteplase in the treatment of acute myocardial infarction (ASSENT-2 Investigators 1999). The table contains the risk ratios (relative risks) for a number of in-hospital cardiac events and procedures, for patients receiving tenecteplase, compared to those receiving alteplase.1

Identify and comment on those cardiac events and procedures for which patients on alteplase had a significant higher risk of experiencing than those on tenecteplase. Note: the key to the cardiac procedures is given in the table footnote. The Killip scale is a classification system for heart failure in patients with acute myocardial infarction, and varies from I (least serious, no heart failure, 5 per cent expected mortality), to IV (most serious, cardiogenic shock, 90 per cent expected mortality).

1As a background note: rapid infusion of alteplase, with aspirin and heparin, is the current gold standard for pharmacological reperfusion in acute myocardial infarction. Tenecteplase is a mutant of alteplase with fewer of the limitations of alteplase.

158 CH 13 TESTING HYPOTHESES ABOUT THE RATIO OF TWO POPULATION PARAMETERS

Testing the odds ratio

Here the null hypothesis is that the population odds ratio is not significantly different from 1. That is:

H0: population odds ratio = 1

H1: population odds ratio =1

In other words, in the population, if H0 is true the risk factor in question does not significantly increase or decrease the odds for the condition or disease. Only if the p value for the sample odds ratio is less than 0.05, can you reject the null hypothesis, and conclude that the risk factor is statistically significant.

An example from practice

Table 13.3 is from an unmatched case-control study into the effect of passive smoking as a risk factor for coronary heart disease (CHD), in Chinese women who had never smoked (He et al. 1994). The cases were patients with CHD, the controls women without CHD. The study looked at both passive smoking at home from husbands who smoked, and at work from smoking co-workers. The null hypotheses were that the population odds ratio was equal to 1, both at home and at work, i.e. passive smoking has no effect on the odds for CHD. The

Table 13.3 Odds ratios, 95 per cent confidence intervals and p values, from an unmatched case-control study into the effect of passive smoking as a risk factor for coronary heart disease. The cases were patients with coronary heart disease, the controls individuals without coronary heart disease. Reproduced from BMJ, 308, 380–4, courtesy of BMJ Publishing Group

 

 

Adjusted odds ratio

 

 

 

(95% confidence interval)

P value

Final model (factors 1 to 7):

 

 

1

Age (years)

1.13 (1.04 to 1.22)

0.003

2

History of hypertension

2.47 (1.14 to 5.36)

0.022

3

Type A personality

2.83 (1.31 to 6.37)

0.008

4

Total cholesterol (mg/dl)

1.02 (1.01 to 1.03)

0.0006

5

High density lipoprotein cholesterol (mg/dl)

0.94 (0.90 to 0.98)

0.003

6

Passive smoking from husband

1.24 (0.56 to 2.72)

0.60

7

Passive smoking at work

1.85 (0.86 to 4.00)

0.12

Other model (factors 1 to 5 and passive smoking at work)

1.95 (0.90 to 4.10)

0.087

Other model (factors 1 to 5 and passive smoking from

2.36 (1.01 to 5.55)

0.049

 

husband or at work, or both)

 

 

Adjusted for the other variables in the final model.

Adjusted for the first five varibles above; odds ratios for these variables in the other models were essentially the same as those shown above and are not shown.

TESTING THE ODDS RATIO

159

table contains the adjusted odds ratios for CHD for a number of risk factors, with 95 per cent confidence intervals and p values.

As you can see, the adjusted odds ratio for CHD because of passive smoking from the husband was 1.24, with a p value of 0.60, so you cannot reject the null hypothesis. You conclude that passive smoking from husbands is not a statistically significant risk factor for CHD in wives. The same conclusions can be drawn for the odds ratio of 1.85 for passive smoking at work, p value equals 0.12.

Exercise 13.2 In Table 13.3, identify those risk factors which are statistically significant for CHD in the population from whom this sample of women was drawn.